Research & Literature

A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy.

Satoh M, Tanaka S, Ceribelli A, et al.

Clinical reviews in allergy & immunology 2017; (52(1)):1-19 doi:10.1007/s12016-015-8510-y.

Risk of myocardial infarction and ischaemic stroke in adults with polymyositis and dermatomyositis: a general population-based study.

Rai SK, Choi HK, Sayre EC, Aviña-Zubieta JA

Rheumatology (Oxford, England) 2016; (55(3)):461-9 doi:10.1093/rheumatology/kev336.

Immune-mediated statin myopathy.

Loganathan P, Oddis CV, Aggarwal R

Expert review of clinical immunology 2016; (12(1)):33-8 doi:10.1586/1744666X.2016.1103181.

Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial.

Ruperto N, Pistorio A, Oliveira S, et al.

Lancet (London, England) 2016; (387(10019)):671-678 doi:10.1016/S0140-6736(15)01021-1.

A Rare Case of Sporadic Inclusion Body Myositis (s-IBM).

Acharya S, Shukla S, Kitey P, et al.

Journal of clinical and diagnostic research : JCDR 2016; (10(1)):OD07-8 doi:10.7860/JCDR/2016/14902.7111.

Causes of creatine kinase levels greater than 1000 IU/L in patients referred to rheumatology.

Leverenz D, Zaha O, Crofford LJ, Chung CP

Clinical rheumatology 2016; (35(6)):1541-7 doi:10.1007/s10067-016-3242-9.

Risk of Malignancy in Dermatomyositis and Polymyositis.

Qiang JK, Kim WB, Baibergenova A, Alhusayen R

Journal of cutaneous medicine and surgery 2017; (21(2)):131-136 doi:10.1177/1203475416665601.

CPK Measurements and ECT in Polymyositis: A Case Report.

Delucia B, Patel R, Yacoub A, Francis A

Journal of psychiatric practice 2016; (22(6)):481-483 doi:10.1097/PRA.0000000000000191.

The Correlation of Muscle Biopsy Scores with the Clinical Variables in Idiopathic Inflammatory Myopathies.

Wangkaew S, Suwansirikul S, Aroonrungwichian K, et al.

The open rheumatology journal 2016; (10()):141-149 doi:10.2174/1874312901610010141.

2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.

Aggarwal R, Rider LG, Ruperto N, et al.

Annals of the rheumatic diseases 2017; (76(5)):792-801 doi:10.1136/annrheumdis-2017-211400.

Integrated Diagnosis Project for Inflammatory Myopathies: An association between autoantibodies and muscle pathology.

Suzuki S, Uruha A, Suzuki N, Nishino I

Autoimmunity reviews 2017; (16(7)):693-700 doi:10.1016/j.autrev.2017.05.003.

Idiopathic inflammatory myopathy and the risk of venous thromboembolism: a meta-analysis.

Lee YH, Song GG

Rheumatology international 2017; (37(7)):1165-1173 doi:10.1007/s00296-017-3735-0.

Idiopathic inflammatory myopathies - a guide to subtypes, diagnostic approach and treatment.

Oldroyd A, Lilleker J, Chinoy H

Clinical medicine (London, England) 2017; (17(4)):322-328 doi:10.7861/clinmedicine.17-4-322.

Clinicopathologic features of myositis patients with CD8-MHC-1 complex pathology.

Ikenaga C, Kubota A, Kadoya M, et al.

Neurology 2017; (89(10)):1060-1068 doi:10.1212/WNL.0000000000004333.

Increased risk of venous thromboembolism associated with polymyositis and dermatomyositis: a meta-analysis.

Li Y, Wang P, Li L, et al.

Therapeutics and clinical risk management 2018; (14()):157-165 doi:10.2147/TCRM.S157085.

Immune Mediated Necrotizing Myopathy: Where do we Stand?

Mohammed AGA, Gcelu A, Moosajee F, et al.

Current rheumatology reviews 2019; (15(1)):23-26 doi:10.2174/1573397114666180406101850.

Update on outcome assessment in myositis.

Rider LG, Aggarwal R, Machado PM, et al.

Nature reviews. Rheumatology 2018; (14(5)):303-318 doi:10.1038/nrrheum.2018.33.

Cardiopulmonary factors affecting 6-min walk distance in patients with idiopathic inflammatory myopathies.

Mugii N, Someya F

Rheumatology international 2018; (38(8)):1443-1448 doi:10.1007/s00296-018-4050-0.

Systematic review of rituximab for autoimmune diseases: a potential alternative to intravenous immune globulin.

MacIsaac J, Siddiqui R, Jamula E, et al.

Transfusion 2018; (58(11)):2729-2735 doi:10.1111/trf.14841.

Statins, myalgia, and rhabdomyolysis.

Tournadre A

Joint bone spine 2020; (87(1)):37-42 doi:10.1016/j.jbspin.2019.01.018.

Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines [corrected].

Meyer A, Scirè CA, Talarico R, et al.

RMD open 2018; (4(Suppl 1)):e000784 doi:10.1136/rmdopen-2018-000784.

[Idiopathic inflammatory myopathies. A review].

Acosta I, Matamala JM, Jara P, et al.

Revista medica de Chile 2019; (147(3)):342-355 doi:10.4067/S0034-98872019000300342.

Interstitial Lung Disease in Polymyositis and Dermatomyositis.

Long K, Danoff SK

Clinics in chest medicine 2019; (40(3)):561-572 doi:10.1016/j.ccm.2019.05.004.

Association of Dermatomyositis Sine Dermatitis With Anti-Nuclear Matrix Protein 2 Autoantibodies.

Inoue M, Tanboon J, Hirakawa S, et al.

JAMA neurology 2020; (77(7)):872-877 doi:10.1001/jamaneurol.2020.0673.

Where are we moving in the classification of idiopathic inflammatory myopathies?

Tanboon J, Uruha A, Stenzel W, Nishino I

Current opinion in neurology 2020; (33(5)):590-603 doi:10.1097/WCO.0000000000000855.

The Low Prevalence of Inclusion Body Myositis in an Outpatient Rheumatology Myositis Cohort.

Edigin E, Hassan AS, Mathur T, Manadan A

Cureus 2020; (12(8)):e9873 doi:10.7759/cureus.9873.

Immune-mediated necrotizing myopathy: clinical features and pathogenesis.

Allenbach Y, Benveniste O, Stenzel W, Boyer O

Nature reviews. Rheumatology 2020; (16(12)):689-701 doi:10.1038/s41584-020-00515-9.

Prevalence of interstitial lung disease in polymyositis and dermatomyositis: A meta-analysis from 2000 to 2020.

Sun KY, Fan Y, Wang YX, et al.

Seminars in arthritis and rheumatism 2021; (51(1)):175-191 doi:10.1016/j.semarthrit.2020.11.009.

Dermatomyositis with exfoliation of esophageal mucosa: A case report.

Zheng W, Zhang H, Zhang X, Liu Y

Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 2021; (46(1)):104-107 doi:10.11817/j.issn.1672-7347.2021.190258.

Juvenile Dermatomyositis: Advances in Pathogenesis, Assessment, and Management.

Leung AKC, Lam JM, Alobaida S, et al.

Current pediatric reviews 2021; (17(4)):273-287 doi:10.2174/1573396317666210426105045.

Analysis of risk factors of interstitial lung disease and mortality rates in Chinese patients with idiopathic inflammatory myopathy.

Bai Z, Shen G, Dong L

International journal of rheumatic diseases 2021; (24(6)):815-827 doi:10.1111/1756-185X.14128.

Increased long-term risk of heart failure and other adverse cardiac outcomes in dermatomyositis and polymyositis: Insights from a nationwide cohort.

Yafasova A, Diederichsen LP, Schou M, et al.

Journal of internal medicine 2021; (290(3)):704-714 doi:10.1111/joim.13309.

High-Resolution CT Findings of Myositis-Related Interstitial Lung Disease.

Egashira R

Medicina (Kaunas, Lithuania) 2021; (57(7)) doi:10.3390/medicina57070692.

Polymyositis: does it really exist as a distinct clinical subset?

Leclair V, Notarnicola A, Vencovsky J, Lundberg IE

Current opinion in rheumatology 2021; (33(6)):537-543 doi:10.1097/BOR.0000000000000837.

Immune-mediated necrotizing myopathy: Unusual presentations of a treatable disease.

Nicolau S, Milone M, Tracy JA, et al.

Muscle & nerve 2021; (64(6)):734-739 doi:10.1002/mus.27435.

Cardiovascular events in adult polymyositis and dermatomyositis: a meta-analysis of observational studies.

Xiong A, Hu Z, Zhou S, et al.

Rheumatology (Oxford, England) 2022; (61(7)):2728-2739 doi:10.1093/rheumatology/keab851.

Idiopathic inflammatory myopathies: CT characteristics of interstitial lung disease and their association(s) with myositis-specific autoantibodies.

Laporte A, Mariampillai K, Allenbach Y, et al.

European radiology 2022; (32(5)):3480-3489 doi:10.1007/s00330-021-08411-w.

When Statins Get Physical: A Curious Cause of Statin Myopathy.

Patel PP, Jackson CD

Southern medical journal 2022; (115(4)):266-269 doi:10.14423/SMJ.0000000000001379.

Antibody Therapies in Autoimmune Inflammatory Myopathies: Promising Treatment Options.

Zeng R, Glaubitz S, Schmidt J

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2022; (19(3)):911-921 doi:10.1007/s13311-022-01220-z.

The Utility of Myositis Specific Antibodies in Clinical Practice.

Biddle K, Taylor MD, Linstead SE, Kiely PDW

The journal of applied laboratory medicine 2022; (7(5)):1189-1201 doi:10.1093/jalm/jfac038.

Thrombin generation potential is increased in patients with autoimmune inflammatory myopathies.

Kuszmiersz P, Siwiec-Koźlik A, Pacholczak-Madej R, et al.

Advances in medical sciences 2022; (67(2)):346-352 doi:10.1016/j.advms.2022.08.005.

The pattern of MHC class I expression in muscle biopsies from patients with myositis and other neuromuscular disorders.

Milisenda JC, Pinal-Fernandez I, Lloyd TE, et al.

Rheumatology (Oxford, England) 2023; (62(9)):3156-3160 doi:10.1093/rheumatology/kead052.

Clinical Characteristics and Risk Factors of Polymyositis and Dermatomyositis Combined with Interstitial Lung Disease in Patients Residing in the Northeast Sichuan Province of China.

Li T, Tang ZY, Zhang QB, et al.

Current rheumatology reviews 2023; (19(4)):455-462 doi:10.2174/1573397119666230330082452.

The wide variety of methotrexate dosing regimens for the treatment of atopic dermatitis: a systematic review.

Caron AGM, Bloem M, El Khattabi H, et al.

The Journal of dermatological treatment 2024; (35(1)):2292962 doi:10.1080/09546634.2023.2292962.

Transcriptome analysis of skeletal muscle in dermatomyositis, polymyositis, and dysferlinopathy, using a bioinformatics approach.

Jeong HN, Lee TG, Park HJ, et al.

Frontiers in neurology 2023; (14()):1328547 doi:10.3389/fneur.2023.1328547.

PM10 increases mortality risk in rheumatoid arthritis-associated interstitial lung disease.

Kim SH, Kim SY, Yoon HY, Song JW

RMD open 2024; (10(1)) doi:10.1136/rmdopen-2023-003680.

Polymyositis is a rare and favourable outcome subtype of idiopathic inflammatory myopathy in Chinese patients.

Sun C, Tian X, Yang H, et al.

Clinical and experimental rheumatology 2024; (42(2)):302-308 doi:10.55563/clinexprheumatol/7v9d2x.

Effect of sirolimus on muscle in inclusion body myositis observed with magnetic resonance imaging and spectroscopy.

Reyngoudt H, Baudin PY, Caldas de Almeida Araújo E, et al.

Journal of cachexia, sarcopenia and muscle 2024; (15(3)):1108-1120 doi:10.1002/jcsm.13451.

A Review of Antisynthetase Syndrome-Associated Interstitial Lung Disease.

Patel P, Marinock JM, Ajmeri A, Brent LH

International journal of molecular sciences 2024; (25(8)) doi:10.3390/ijms25084453.

Systemic sclerosis associated myopathy: how to treat.

Selva-O'Callaghan A, Guillen-Del-Castillo A, Gil-Vila A, et al.

Current treatment options in rheumatology 2023; (9(4)):151-167 doi:10.1007/s40674-023-00206-y.

Inclusion body myositis: Correcting impaired mitochondrial and lysosomal autophagy as a potential therapeutic strategy.

Brady S, Poulton J, Muller S

Autoimmunity reviews 2024; (23(11)):103644 doi:10.1016/j.autrev.2024.103644.

Inclusion Body Myositis: A Late Diagnosis Case Report.

Hernández-Rivero DA, Bazán-Rodríguez L, Cruz-Domínguez MDP, et al.

Reumatologia clinica 2024; (20(9)):511-512 doi:10.1016/j.reumae.2024.10.002.

Recognition of Idiopathic Inflammatory Myopathies Underlying Interstitial Lung Diseases.

Morina G, Sambataro D, Libra A, et al.

Diagnostics (Basel, Switzerland) 2025; (15(3)) doi:10.3390/diagnostics15030275.

Serum creatine kinase: requesting and interpreting results.

Walters J, Gailani G

Practical neurology 2025; (25(4)):323-329 doi:10.1136/pn-2024-004422.

Long-term outcomes of idiopathic inflammatory myopathies: a large-scale longitudinal cohort study.

Chen Y, Zhu L, Zong C, et al.

Journal of autoimmunity 2025; (154()):103435 doi:10.1016/j.jaut.2025.103435.

Remission and low disease activity definitions in adult idiopathic inflammatory myopathies: A narrative review by myositis clinical trials consortium (MCTC).

Pongtarakulpanit N, Keret S, Kothari V, et al.

Autoimmunity reviews 2025; (24(10)):103879 doi:10.1016/j.autrev.2025.103879.

The value of myositis-specific autoantibodies in the diagnosis of idiopathic inflammatory myopathy and tumor risk prediction.

Shi L, Min R, Wu Y, et al.

The Journal of international medical research 2025; (53(8)):3000605251362969 doi:10.1177/03000605251362969.

Idiopathic Inflammatory Myopathy With Normal Creatine Kinase Levels in an Elderly Patient: A Diagnostic Challenge.

Chilakuluri P, Debnath V, Barakat A, et al.

Cureus 2025; (17(12)):e100301 doi:10.7759/cureus.100301.

Evaluation of protein expression and oxidative stress index in Duchenne muscular dystrophy.

Rizk SK, Ezzat EM, Abuhegazy A, El-Ghlban S

Pediatric research 2026; doi:10.1038/s41390-025-04585-x.